JBM (Healthcare) Ltd. has issued a positive profit alert, indicating a significant improvement in its financial performance for the year ended 31 March 2025. The company anticipates an increase in consolidated profit attributable to shareholders by at least 50% compared to the previous year. This expected rise in profit is largely due to robust sales of key brands such as Ho Chai Kung in the branded medicines segment, alongside Po Chai Pills and Flying Eagle Woodlok Oil in the proprietary Chinese medicines segment. The company's successful and targeted brand management campaigns have been pivotal in achieving these results. The announcement highlights effective sales and marketing strategies across both offline and online channels and underscores the company's strategic focus on capitalizing on the growth potential of branded consumer healthcare products in regions such as Hong Kong, Macau, and the Greater Bay Area. The reported figures are preliminary and based on unaudited management accounts, with final details to be disclosed in the forthcoming annual results announcement expected on 12 June 2025.